Pradaxa = HVDP (dabi­ga­tran = HVD?) [Regulatives / Guidelines]

posted by Shuanghe  – Spain, 2015-09-22 18:53 (3931 d 03:35 ago) – Posting: # 15451
Views: 19,713

Hi all,

❝ ❝ BTW: Do you think this sort of BE evaluation is not an "Eintagsfliege" (nine day wonder, ephemera), specific for dabigatran?


❝ No idea. Let’s ask generic companies to follow the path the innovator walked?


There's another guidance of rivaroxaban which takes the same approach as dabigatran.

Unfortunately, I've done BE studies for both dabigatran and rivaroxaban and one of the dossiers have been submitted. Now I have to do some additional analysis according to the new requirements and waiting for the deficient letter to come. :-(

By the way, dabigatran is highly variable under fasting condition but not under fed condition. At least based on my 6 studies (EU/US, pilot/pivotal), all fed study showed ISCV < 30% while all fasting study showed ISCV > 40%.

As for rivaroxaban, it's high variable only for 20mg under fasting. under fed, not so much.

All the best,
Shuanghe

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
382 visitors (0 registered, 382 guests [including 15 identified bots]).
Forum time: 22:28 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5